Last reviewed · How we verify
Abreva (DOCOSANOL)
At a glance
| Generic name | DOCOSANOL |
|---|---|
| Sponsor | Haleon Us Holdings |
| Drug class | docosanol |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 2000 |
Approved indications
- Herpes labialis
Common side effects
Key clinical trials
- Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions (PHASE2)
- EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions (PHASE2)
- Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment (PHASE3)
- A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging (NA)
- Topical and Oral Regimen for Skin Health (NA)
- An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis (PHASE2)
- Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abreva CI brief — competitive landscape report
- Abreva updates RSS · CI watch RSS